Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 15Unknown 4Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 705Carcinoma, Non-Small-Cell Lung 473Prostatic Neoplasms 423Neoplasms 384Multiple Myeloma 266Colorectal Neoplasms 257Lung Neoplasms 245Neoplasm Metastasis 234Melanoma 219Leukemia, Myeloid, Acute 193Ovarian Neoplasms 189Pancreatic Neoplasms 177Squamous Cell Carcinoma of Head and Neck 160Carcinoma, Renal Cell 146Recurrence 144Lymphoma 144Glioblastoma 142Lymphoma, Non-Hodgkin 136Stomach Neoplasms 128Triple Negative Breast Neoplasms 127Leukemia, Lymphocytic, Chronic, B-Cell 123Brain Neoplasms 123Carcinoma, Hepatocellular 122Head and Neck Neoplasms 116Uterine Cervical Neoplasms 115Urinary Bladder Neoplasms 115Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Lymphoma, Large B-Cell, Diffuse 104Sarcoma 103Lymphoma, Follicular 100

Interventions

bazedoxifene 1Estrogens, Conjugated (USP) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Risk Reduction Behavior × Clear all
NCT04821141 2025-10-29

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

University of Kansas Medical Center

Phase 2 Active not recruiting
120 enrolled
Breast

Breast Neoplasms, Hot Flashes, Risk Reduction Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡